|drug329||Any drug used to treat Covid-19 Wiki||1.00|
|D007049||Iatrogenic Disease NIH||1.00|
|D058186||Acute Kidney Injury NIH||0.19|
|D012128||Respiratory Distress Syndrome, Adult NIH||0.07|
There is one clinical trial.
The trial was designed to assess the effect of daily dose of 300 mg omega-3 supplements for 2 months on the selected interleukins levels in uninfected people with Covid-19.
Description: pg/mLMeasure: IL-1 beta Time: (2 months ; 60 days )
Description: pg/mlMeasure: IL-6 Time: (2 months ; 60 days )
Description: pg/mlMeasure: TNF alpha Time: (2 months ; 60 days )
Description: mg/dLMeasure: Lipid profile Time: (2 months ; 60 days )
Description: mg/dlMeasure: Fasting blood glucose Time: (2 months ; 60 days )
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports